Methods and compositions for delivery of biologics
Nucleases and methods of using these nucleases for genetic alteration of red blood cells (RBCs), for example for providing for a protein lacking in a monogenic disorder or a biologic for the treatment of exposure to a toxin using genetically altered RBCs.
1. An isolated modified type O negative (type O−) red blood cell (RBC) that secretes a protein that degrades or detoxifies one or more nerve agents, wherein the RBC is derived from a blood type O-negative population of RBC precursor cells comprising (i) a pair of zinc finger nucleases (ZFNs) that cleave an endogenous beta globin gene and (ii) a transgene comprising a sequence encoding the protein, wherein the transgene is integrated into the endogenous beta globin gene of the RBC precursor cell population following cleavage by the pair of ZFNs, and further wherein the transgene integrated into the endogenous beta globin gene is integrated into or between the target sites as shown in SEQ ID NO:1 and SEQ ID NO:2 or into or between the target sites as shown in SEQ ID NO:13 and SEQ ID NO:14, such that expression of the protein is driven by the endogenous promoter of the beta globin gene.
2. The RBC cell of claim 1 , wherein the transgene is integrated into an endogenous beta globin gene such that the transgene is expressed as a fusion protein with polypeptides expressed from the endogenous beta globin gene.
3. The RBC cell of claim 2 , wherein the polypeptides expressed from the endogenous beta globin gene are present on the amino (N)-terminal portion or carboxy (C)-terminal portion of the fusion protein.
4. The RBC cell of claim 1 , wherein the cell expresses fetal hemoglobin.
5. The RBC according to claim 1 wherein the RBC lacks A, B, Rh, and/or Kell blood group antigens.
6. A method of degrading or detoxifying the effects of a nerve agent in a subject in need thereof, the method comprising administering a RBC according to claim 1 to the subject in need thereof.